Atossa Therapeutics (ATOS) restores Nasdaq Capital Market listing compliance

Rhea-AI Filing Summary

Atossa Therapeutics, Inc. received notice from Nasdaq on February 17, 2026 that it has regained compliance with the Nasdaq Capital Market’s minimum bid price listing rule. The company’s stock met the requirement to maintain a closing bid price of at least $1.00 per share for 10 consecutive trading days, achieved as of the close on February 13, 2026.

Atossa had previously been notified on February 21, 2025 that it was out of compliance with the $1.00 minimum bid price and was granted an extension through February 17, 2026 to correct the deficiency. With compliance restored, the company’s common stock will continue to be listed and traded on the Nasdaq Capital Market.

Positive

• Nasdaq listing compliance restored: The company regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum $1.00 bid price for 10 consecutive trading days as of February 13, 2026, allowing its common stock to continue trading on the Nasdaq Capital Market.

Negative

• None.

Insights

Equity markets and listing standards analyst

Regaining Nasdaq compliance removes a delisting overhang and stabilizes listing status.

Atossa Therapeutics has restored compliance with Nasdaq’s minimum $1.00 bid price rule by maintaining that level for 10 consecutive trading days as of February 13, 2026. Nasdaq confirmed compliance on February 17, 2026, resolving the previously disclosed deficiency notice.

This change is important because failure to regain compliance could have led to delisting from the Nasdaq Capital Market, which often reduces liquidity and can limit access to capital markets. Continued listing preserves the company’s exchange visibility and trading venue.

Future investor focus will likely reference the company’s ability to sustain bid-price compliance following the February 17, 2026 confirmation, with subsequent disclosures in periodic reports providing further context on trading performance and any additional interactions with Nasdaq.

0001488039false00014880392026-02-172026-02-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2026

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35610	26-4753208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1448 NW Market Street, Suite 500
Seattle, Washington				98107
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.18 par value		ATOS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 17, 2026, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

As previously disclosed, on February 21, 2025, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was initially given until August 20, 2025 to regain compliance, but the Company subsequently requested an extension. On August 21, 2025, the Company was informed that its deadline to regain compliance was extended by 180 days, or until February 17, 2026.

To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days. This requirement was met as of the close of trading on February 13, 2026. As a result, the Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Atossa Therapeutics, Inc.
Date:	February 17, 2026	By:	/s/ Mark J. Daniel
			Mark J. Daniel Chief Financial Officer (Principal Financial and Accounting Officer)

FAQ

What did Atossa Therapeutics (ATOS) announce in this 8-K filing?

Atossa Therapeutics announced it has regained compliance with Nasdaq’s minimum bid price requirement. Its stock closed at or above $1.00 for 10 straight trading days by February 13, 2026, so its shares will continue trading on the Nasdaq Capital Market.

Why was Atossa Therapeutics (ATOS) previously out of compliance with Nasdaq rules?

Atossa Therapeutics was previously notified on February 21, 2025 that its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. This triggered a deficiency notice under Nasdaq Listing Rule 5550(a)(2) concerning continued listing standards.

How did Atossa Therapeutics (ATOS) regain Nasdaq bid price compliance?

Atossa regained compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days. Nasdaq confirmed that this requirement was satisfied as of the close of trading on February 13, 2026 and formally notified the company on February 17, 2026.

What was the compliance deadline Nasdaq set for Atossa Therapeutics (ATOS)?

Nasdaq initially gave Atossa until August 20, 2025 to regain compliance, then extended the deadline by 180 days to February 17, 2026. The company met the bid price requirement by achieving 10 straight trading days at or above $1.00 before that extended deadline.

Will Atossa Therapeutics (ATOS) remain listed on the Nasdaq Capital Market?

Yes, Atossa’s common stock will continue to be listed and traded on the Nasdaq Capital Market. Regaining compliance with Nasdaq Listing Rule 5550(a)(2) removed the immediate delisting risk tied to its prior sub-$1.00 bid price performance.

What Nasdaq listing rule did Atossa Therapeutics (ATOS) satisfy?

Atossa satisfied Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 per share closing bid price. The company’s stock maintained at least this price for 10 consecutive trading days, leading Nasdaq to confirm that the company was back in full compliance.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 26.8 KB